Needham Maintains Buy on Harmony Biosciences, Lowers Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Harmony Biosciences (NASDAQ:HRMY) but lowers the price target from $53 to $50.
February 23, 2024 | 10:44 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham maintains a Buy rating on Harmony Biosciences but lowers the price target from $53 to $50.
The adjustment in price target by Needham, while maintaining a Buy rating, suggests a positive outlook on HRMY's fundamentals but with a slightly moderated growth expectation. This could lead to a neutral short-term impact on HRMY's stock price as the market digests the revised target alongside the continued endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100